Frederick M. Hudson - 12 Mar 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: Director
Issuer ticker: SUPN
Reported as of: 12 Mar 2026
Net transaction value: -$271,725
SEC form: 4
Accepted by SEC: 16 Mar 2026, 16:07:41 UTC
Prior SEC filing: 25 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Frederick M. Hudson filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 16 Mar 2026.

Key facts

This page summarizes Frederick M. Hudson's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Mar 2026, 16:07.

Change

Previous filing in this sequence was filed on 25 Feb 2026.
Current net transaction value: -$271,725.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438462 Primary reporting owner

Hudson Frederick M.

Relationship: Director
Address: C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 16 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Sale

Transaction value: $271,725
Shares: -5,369
Change %: -8.2%
Price: $50.61
Shares after: 60,413
Date: 12 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.